767 related articles for article (PubMed ID: 17177598)
1. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Lee JC; Vivanco I; Beroukhim R; Huang JH; Feng WL; DeBiasi RM; Yoshimoto K; King JC; Nghiemphu P; Yuza Y; Xu Q; Greulich H; Thomas RK; Paez JG; Peck TC; Linhart DJ; Glatt KA; Getz G; Onofrio R; Ziaugra L; Levine RL; Gabriel S; Kawaguchi T; O'Neill K; Khan H; Liau LM; Nelson SF; Rao PN; Mischel P; Pieper RO; Cloughesy T; Leahy DJ; Sellers WR; Sawyers CL; Meyerson M; Mellinghoff IK
PLoS Med; 2006 Dec; 3(12):e485. PubMed ID: 17177598
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Greulich H; Chen TH; Feng W; Jänne PA; Alvarez JV; Zappaterra M; Bulmer SE; Frank DA; Hahn WC; Sellers WR; Meyerson M
PLoS Med; 2005 Nov; 2(11):e313. PubMed ID: 16187797
[TBL] [Abstract][Full Text] [Related]
3. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
[TBL] [Abstract][Full Text] [Related]
4. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.
Halatsch ME; Gehrke EE; Vougioukas VI; Bötefür IC; A-Borhani F; Efferth T; Gebhart E; Domhof S; Schmidt U; Buchfelder M
J Neurosurg; 2004 Mar; 100(3):523-33. PubMed ID: 15035290
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
[TBL] [Abstract][Full Text] [Related]
9. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
Park AK; Francis JM; Park WY; Park JO; Cho J
Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.
Idbaih A; Aimard J; Boisselier B; Marie Y; Paris S; Crinière E; Carvalho Silva R; Laigle-Donadey F; Rousseau A; Mokhtari K; Thillet J; Sanson M; Hoang-Xuan K; Delattre JY
Neuropathol Appl Neurobiol; 2009 Apr; 35(2):208-13. PubMed ID: 19284481
[TBL] [Abstract][Full Text] [Related]
11. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
12. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
Carey KD; Garton AJ; Romero MS; Kahler J; Thomson S; Ross S; Park F; Haley JD; Gibson N; Sliwkowski MX
Cancer Res; 2006 Aug; 66(16):8163-71. PubMed ID: 16912195
[TBL] [Abstract][Full Text] [Related]
15. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
Kancha RK; Peschel C; Duyster J
J Thorac Oncol; 2011 Feb; 6(2):387-92. PubMed ID: 21252719
[TBL] [Abstract][Full Text] [Related]
16. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.
Jiang J; Greulich H; Jänne PA; Sellers WR; Meyerson M; Griffin JD
Cancer Res; 2005 Oct; 65(19):8968-74. PubMed ID: 16204070
[TBL] [Abstract][Full Text] [Related]
18. Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR.
Becker C; Öcal S; Nguyen HD; Phan T; Keul M; Simard JR; Rauh D
Chembiochem; 2016 Jun; 17(11):990-4. PubMed ID: 26991964
[TBL] [Abstract][Full Text] [Related]
19. Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Kim Y; Apetri M; Luo B; Settleman JE; Anderson KS
Mol Cancer Res; 2015 Apr; 13(4):765-74. PubMed ID: 25573954
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
